Welcome to PRI
Full details about the
Public Health and Emerging Microbial Threats Conference
are available at:
Organizing CommitteeBrian Reese, PhD, JD, MBA, Choate, Hall & Stewart LLP (Boston, MA) Thomas J. Webster, PhD, Northeastern University (Boston, MA) Neil Gordon, BEng, MBA, Guanine, Inc. (Salt Lake City, UT and Montreal, Canada) Susan Gilbert, PhD, Rensselaer Polytechnic Institute (Troy, NY)
Conference ChairsRaj Bawa, MS, PhD, Patent Agent, Bawa Biotech LLC, Ashburn, VA; Adjunct Professor, Rensselaer Polytechnic Institute, Troy, NY; Scientific Advisor, Teva Pharma, Israel Shaker A. Mousa, PhD, MBA, Vice Provost and Professor, Albany College of Pharmacy and Health Sciences, Albany, NY; Chairman & Executive Vice President, The Pharmaceutical Research Institute, Rensselaer, NY
Feb. 11-13, 2016
Attendees at the
5th Pan Arab Hematology Association Conference / 14th Saudi Society of Hematology Conference / in collaboration with the Egyptian Society of Hematology and Research Meeting
were asked to vote on the best lecture, and Dr. Mousa was honored as the recipient!
Dr. Mousa, Dr. Bharali, and Nanomedicine at PRI featured on local Time Warner News television:
CLICK HERE to watch video of Dr. Mousa! CLICK HERE to watch video of Dr. Bharali!
Emerging Therapies for Pancreatic Ductal Carcinoma
–Robert Falcone, Paul J. Davis, Steven C. Stain, and Shaker A. Mousa (2016), Journal of Solid Tumors 6(1):65-77.Read more
Pancreatic ductal adenocarcinoma (PDAC) is a solid tumor mass that grows and metastasizes rapidly. There are no definitive methods for early detection and most patients are diagnosed at a late stage. Those diagnosed at an early stage are eligible for tumor resection. However, many of these patients are soon burdened with tumor recurrence. The tumor grows back aggressively and with resistance to the original chemotherapy. Gemcitabine has been the treatment of choice, but provides only minimal survival prolongation. Researchers are trying to improve the current standard of care by finding different methods to improve treatment efficacy and reduce side effects. This review emphasizes recent data on targeting the tumor using antifibrotic, nanotargeted, and dendritic cell therapies. Antifibrotic therapy aims to reduce tumor fibrosis, which prevents adequate chemotherapy penetration. Nanotargeted therapy offers precise targeting of cancer cells and chemotherapy delivery. Dendritic cell vaccines stimulate the body’s immune system to target PDAC cells. These three treatment methods or a combination of them might improve the lifespan and quality of life for PDAC patients.
Date (Phoenix dactylifera) Polyphenolics and Other Bioactive Compounds: A Traditional Islamic Remedy’s Potential in Prevention of Cell Damage, Cancer Therapeutics and Beyond
–Bibi R. Yasin, Hassan A. N. El-Fawal and Shaker A. Mousa (2015), International Journal of Molecular Sciences 16:30075-30090.Read more
This review analyzes current studies of the therapeutic effects of Phoenix dactylifera, or date palm fruit, on the physiologic system. Specifically, we sought to summarize the effects of its application in preventing cell damage, improving cancer therapeutics and reducing damage caused by conventional chemotherapy. Phoenix dactylifera exhibits potent anti-oxidative properties both in vitro and in vivo. This allows the fruit to prevent depletion of intrinsic protection from oxidative cell damage and assist these defense systems in reducing cell damage. Macroscopically, this mechanism may be relevant to the prevention of various adverse drug events common to chemotherapy including hepatotoxicity, nephrotoxicity, gastrotoxicity, and peripheral neuropathy. While such effects have only been studied in small animal systems, research suggests a potential application to more complex mammalian systems and perhaps a solution to some problems of chemotherapy in hepato-compromised and nephro-compromised patients.